Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection
Brief Summary: The purpose of this study is to investigate the safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C infection.


Options:
A: Inclusion Criteria:

* Willing and able to provide written informed consent
* HCV RNA ≥ 10\^4 IU/mL
* HCV genotype 3
* Chronic HCV infection (≥ 6 months)
* Females of childbearing potential must have a negative serum pregnancy test
* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception

Exclusion Criteria:

* Current or prior history of clinically-significant illness (other than HCV) that may interfere with subject treatment, assessment or compliance with the protocol
* Screening ECG with clinically significant abnormalities
* Laboratory results outside of acceptable ranges at Screening
* Pregnant or nursing female or male with pregnant female partner
* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)
* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
B: Inclusion Criteria:

* Males or females aged 18 to 70 years, inclusive, at screening
* Documented chronic genotype 1, 2, or 3 HCV infection
* No previous treatment with HCV antiviral mediations
* Body mass index (BMI) of greater than 18 kg/m2, but not exceeding 36 kg/m2.
* Liver biopsy obtained within 3 years prior to the Day 1 visit, with a fibrosis classification of non-cirrhotic as judged by a local pathologist
* Willing to refrain from beginning any new exercise regimens during the first 3 months of the study
* Fasting blood glucose ≤ 300 mg/dl and/or glycosylated hemoglobin (HbA1c) ≤ 8
* History of hypertension only if managed effectively on a stable regimen of two or fewer antihypertensives for at least three (3) months prior to screening

Exclusion Criteria:

* Females who were breastfeeding
* Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study
* Positive test at Screening for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab.
* History of any other clinically significant chronic liver disease
* Treatment with herbal/natural remedies with antiviral activity within 30 days prior to baseline.
* Significant history of immunologically mediated disease, cardiac or pulmonary disease, seizure disorder or anticonvulsant use
* History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease
* Use of medications associated with QT prolongation within 30 days prior to dosing
* Screening electrocardiogram (ECG) QTc value greater than 450 ms and/or clinically significant ECG findings
* Personal or family history of Torsade de pointes.
* Positive results for drugs of abuse test at screening
* Abnormal hematological and biochemical parameters, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 5 times the upper limit of the normal range (ULN)
* History of major organ transplantation with an existing functional graft
* History of uncontrolled thyroid disease or abnormal thyroid-stimulating hormone (TSH) levels at screening
* Clinically significant drug allergy to nucleoside/nucleotide analogs
* History or current evidence of psychiatric illness, immunologic disorder, pulmonary, cardiac disease, seizure disorder, cancer or history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study
* History of systemic antineoplastic or immunomodulatory treatment within 6 months prior to dosing, or the expectation of such treatment during the study
C: Inclusion Criteria:

* Male or female, ages 18 to 65 years
* Documented chronic HCV infection, genotype 1a or 1b
* Treatment-naïve
* BMI = 18 - 35 kg/m2

Exclusion Criteria:

* Female patients who are pregnant or breast-feeding
* Previous treatment for HCV infection
* HIV or HBV positive
* Evidence of cirrhosis on previous liver biopsy or on previous imaging studies
* History of any other known cause of liver disease;
D: Inclusion Criteria:

* Genotype 1 hepatitis C infection (confirmed at screening)
* Have previously received peginterferon-based therapy for at least 24 weeks with documented HCV RNA at last measurement and relapsed within 1 year of last taking medication
* Liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection
* Must agree to use 2 forms of effective contraception throughout study (both males and females)

Exclusion Criteria:

* Infection with HIV or non-genotype 1 hepatitis C
* Liver disease not related to hepatitic C infection
* Hepatic decompensation
* Significant laboratory abnormalities or other active diseases
* Pregnant or planning to become pregnant

Answer: C